Press Releases


Press Releases

November 12, 2021
BURNABY, British Columbia , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer , Xenon’s President and Chief Executive Officer, along with Sherry Aulin , Xenon’s Chief Financial Officer, will ...
October 4, 2021
BURNABY, British Columbia , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration ...
July 7, 2021
Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ET BURNABY, British Columbia , July 07, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided an update on its ongoing XEN1101 Phase 2b “X-TOLE” ...
April 8, 2021
BURNABY, British Columbia , April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor ...
March 29, 2021
BURNABY, British Columbia , March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a fireside chat at the following virtual investor conference: Stifel 3 rd Annual CNS Day ...
March 9, 2021
BURNABY, British Columbia , March 09, 2021 (GLOBE NEWSWIRE) --   Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that ...
March 8, 2021
U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021 BURNABY, British Columbia , March 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today ...